Exciting developments for new treatment research
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
Search results
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
We are currently funding a range of exciting projects and programmes, all of which aim to enhance our understanding of inherited sight loss, and inform the development of treatments for the estimated two million people affected worldwide.
The project aims to develop a cost effective method of examining the entire ABCA4 gene to look for variations that might cause disease.
Retina UK has invested more than £16million into cutting-edge research since the charity was founded in 1976.
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
This page explains the different types of genetic tests: diagnostic testing, predictive testing, carrier testing and research testing
James Birtley is a Retina UK supporter and volunteer who is living with retinitis pigmentosa. He is also a scientist with a particular interest in the structure of proteins, the complex molecules that form the building blocks of our bodies.
Thank you to all those who completed our recent Sight Loss Survey – almost 700 of you took the time to share your experiences.
Jenny Dewing is a postdoctoral researcher working on a Retina UK-funded project with Dr Arjuna Ratnayaka at the University of Southampton.
The Retina UK community is sometimes targeted by adverts online or in social media, offering invasive treatments for inherited sight loss.